THE DEMONSTRATION PROJECT: The Medicare Modernization Act of 2003, authorized Medicare to pay for expensive medications, not generally covered under Part B, for 50,000 of approximately 500,000 eligible Medicare beneficiaries. A “lottery” system was designed to select which eligible beneficiaries would participate in the project. ELIGIBLE MEDICARE BENEFICIARY:Any Medicare beneficiary with both Part A and … Read more

On February 28, 2005 the manufacturers of Tysabri, Biogen Idec and Elan Corporation, announced the voluntary suspension of the Multiple Sclerosis drug from the market and from all clinical trials. According to the companies’ press release: This decision is based on very recent reports of two serious adverse events that have occurred in patients treated … Read more

On February 28, 2005 the manufacturers of Tysabri, Biogen Idec and Elan Corporation, announced the voluntary suspension of the Multiple Sclerosis drug from the market and from all clinical trials.  According to the companies’ press release: This decision is based on very recent reports of two serious adverse events that have occurred in patients treated … Read more

SUMMARY: Despite the fact that the Replacement Drug Demonstration Project (the Demonstration Project) is supposed to cover expensive medications not generally covered under Medicare Part B, some of the medications covered by the Demonstration Project may be covered under Medicare Part B when they are administered incident to a physician’s professional services. The multiple sclerosis … Read more

In our Weekly Alert of August 12, 2004, the Center for Medicare Advocacy reviewed the Medicare Discount Drug Cards. One of the issues we raised concerned the difficulty, for people who use certain MS drugs, of entering the correct frequency and dosage amounts in the Medicare drug card web site. This information must be entered … Read more